EPS for DURECT Corporation (DRRX) Expected At $-0.03

October 14, 2018 - By Richard Conner

DURECT Corporation (NASDAQ:DRRX) LogoInvestors sentiment increased to 1.8 in 2018 Q2. Its up 0.09, from 1.71 in 2018Q1. It is positive, as 12 investors sold DURECT Corporation shares while 18 reduced holdings. 19 funds opened positions while 35 raised stakes. 74.53 million shares or 5.13% more from 70.89 million shares in 2018Q1 were reported.
Proshare Advsr Lc reported 0% in DURECT Corporation (NASDAQ:DRRX). Tiaa Cref Inv Ltd Limited Liability Company invested 0% in DURECT Corporation (NASDAQ:DRRX). Plante Moran Fincl Advsrs Limited Company invested in 676 shares or 0% of the stock. Wells Fargo Mn holds 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX) for 468,961 shares. Amalgamated Savings Bank stated it has 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX). Tocqueville Asset Lp has 0.02% invested in DURECT Corporation (NASDAQ:DRRX). Citigroup owns 22,516 shares. First Eagle Invest Limited Liability Corporation has invested 0.09% in DURECT Corporation (NASDAQ:DRRX). Balyasny Asset Ltd Liability Corporation accumulated 60,944 shares. Glenmede Company Na reported 5,000 shares. 5,155 are owned by Bnp Paribas Arbitrage. Cubist Systematic Strategies Limited Liability Corporation reported 22,409 shares stake. Piedmont Advsrs Limited Liability Corp holds 2,722 shares. Ny State Common Retirement Fund holds 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX) for 149,600 shares. Prelude Cap Lc has 363,831 shares for 0.04% of their portfolio.

Analysts expect DURECT Corporation (NASDAQ:DRRX) to report $-0.03 EPS on November, 7.They anticipate $0.07 EPS change or 175.00 % from last quarter’s $0.04 EPS. After having $-0.04 EPS previously, DURECT Corporation’s analysts see -25.00 % EPS growth. The stock increased 1.04% or $0.01 during the last trading session, reaching $0.97. About 166,227 shares traded. DURECT Corporation (NASDAQ:DRRX) has declined 24.22% since October 14, 2017 and is downtrending. It has underperformed by 39.84% the S&P500.

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company has market cap of $157.14 million. The firm offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials for pharmaceutical and medical devices under the LACTEL brand. It currently has negative earnings. The Company’s product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase 1 development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival.

More news for DURECT Corporation (NASDAQ:DRRX) were recently published by: Seekingalpha.com, which released: “DURECT Corporation appoints Michael H. Arenberg as Chief Financial Officer” on October 01, 2018. Seekingalpha.com‘s article titled: “DURECT +13% on receiving marketing authorization for methydur sustained release capsules for ADHD in Taiwan” and published on September 18, 2018 is yet another important article.

DURECT Corporation (NASDAQ:DRRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>